Elongase genes and uses thereof
CA 2633074 C · Owner: Abbott Laboratories · Inventors: Das, Tapas; Thurmond, Jennifer; Leonard, Amanda Eun-Yeong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e. 'elongases') and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogama linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids such as arachidonic acid (AA), docosahexaenoic acid (DHA) EPA, adrenic acid, $g(v)6-docosapentaenoic acid or $g(v)3--docosapentaenoic acid which may be added to pharmaceutical compositions …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 30, 1999 and granted June 25, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 30, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 30, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.